Discordant responses to two classes of drugs acting on the renin-angiotensin system

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 2, Issue 1, 2001, Pages 25-30

  Sever, Peter S ^a   Limmie Chang, C ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin receptor antagonist; Hypertension

Indexed keywords

ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; BIPHENYL DERIVATIVE; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; RENIN; TETRAZOLE DERIVATIVE;

AGED; ARTICLE; BLOOD; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; CROSS-OVER STUDIES; DIASTOLE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; LISINOPRIL; MALE; MIDDLE AGED; RENIN; RENIN-ANGIOTENSIN SYSTEM; SYSTOLE; TETRAZOLES;

EID: 0035295610     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2001.004     Document Type: Article

References (18)

1. Prescott-Clarke P, Primatesta P. The Health Survey for England 1996. London, HMSO: 1998.
2. Sever PS. The heterogeneity of hypertension. Eur Heart J 1999;1(Suppl L):L10-3.
3. Materson BJ, Reda DJ, Cushman WC et al. Single drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. New Eng J Med 1993;328:914-21.
4. The Sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
5. 1999 World Health Organisation - International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Sub-committee. J Hypertens 1999;17:151-83.
6. Ramsay LE, Williams B, Johnston GD et al. for the British Hypertension Society. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. Br Med J 1999;319:630-5.
7. Jones JK, Gorkin L, Lian JF, Staffa JA, Fletcher AP. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population. Br Med J 1995;311:293-5.
8. Neutal JM. Safety and efficacy of angiotensin II receptor antagonists. Am J Cardiol 1999; 84(suppl 2):13K-17K.
9. Birkinhager WH, de Leeuw PW. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J Hypertens 1999;17:873-81.
10. Menard J and Catt, KJ. Measurement of renin activity, concentration and substrate in rat plasma by radioimmunoassay of Angiotensin I. Endocrinology 1972; 90:422-30.
11. McNemar Q. Note on the sampling error of the differences between correlated proportions or percentages. Psychometrika. 1947;12:153-7.
12. Hills M, Armitage P. The two-period-cross-over clinical trial. Br J Clin Pharmac. 1979;8:7-19.
13. Gill JS, Zezulka AV, Beevers DG, Davis P. Relation between initial blood pressure and its fall with treatment. Lancet 1985;1:567-69.
14. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999;353:2008-13.
15. Attwood S, Bird R, Burch K et al. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedipine. J Hypertens 1994;12:223-6.
16. Johnston CI, Burrell LM. Evolution of the blockade of the renin-angiotensin system. J Human Hypertens 1995;9:375-80.
17. Juillerat L, Nussberger J, Menard J et al. Determinants of angiotensin II generation during converting enzyme inhibition. Hypertension 1990;16:564-72.
18. Siragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 2000;35:1074-84.